The use of transcriptomic data in developing biomarkers in breast cancer
January 8, 2024
Maher AlbitarMD, Andre GoyMD, Andrew PecoraMD, Deena GrahamMD, Donna McNamaraMD, Ahmad CharifaMD, Andrew IPMD, Wanlong Ma MS, StanleyWaintraubMD Abstract HER2 and hormone receptors are biomarkers for selecting breast cancer therapy and predicting outcomes. In the era of antibody-drug conjugates (ADC), a relatively low HER2 expression level is adequate for targeting